Immune activation in patients with locally advanced cervical cancer treated with ipilimumab following definitive chemoradiation (GOG-9929)

PURPOSE: A Phase I clinical trial (GOG-9929) examined the safety and efficacy of adjuvant immune modulation therapy with the checkpoint inhibitor ipilimumab (anti-CTLA4) following chemoradiation therapy (CRT) for newly diagnosed node-positive human papillomavirus (HPV)-related cervical cancer. To be...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: DA SILVA, Diane M., ENSERRO, Danielle M., MAYADEV, Jyoti S., SKEATE, Joseph G., MATSUO, Koji, PHAM, Huyen Q., LANKES, Heather A., MOXLEY, Katherine M., GHAMANDE, Sharad A., LIN, Yvonne G., SCHILDER, Russell J., BIRRER, Michael J., KAST, W. Martin
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7642021/
https://ncbi.nlm.nih.gov/pubmed/32816895
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-20-0776
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados